A randomized controlled trial of long term effect of BCM guided fluid management in MHD patients (BOCOMO study): rationales and study design

BMC Nephrology

Li Zuo^1,12  Yulan Shen⁷  Yonghui Mao^1,10  Yingchun Ma⁶  Yi Sun⁹  Wenjun Liu⁸  Shan Lin^1,15  Weiming Sun⁵  Ping Yuan^1,11  Moyan Qiu¹  Mao Li^1,14  Jinghong Lei^1,16  Jinsheng Xu^1,13  Jijun Li²  Jianwei Ren³  Gang Long⁴  Li Liu^1,12 

[1] Renal Department, Beijing Wangjing Hospital, Beijing, China;Renal Department, PLA General Hospital First Hospital, Beijing, China;Renal Department, Aviation General Hospital, Beijing, China;Renal Department, Tianjin Union Medicine Center, Tianjin, China;Renal Department, Beijing Shijitan Hospital, Beijing, China;Renal Department, China Rehabilitation Research Center, Beijing Boai Hospital, Beijing, China;Renal Department, Miyun Hospital, Beijing, China;Renal Department, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Guanganmen, China;Renal Department, Capital University Fuxing Hospital, Beijing, China;Renal Department, Beijing Hospital of Ministry of Health, Beijing, China;Renal Department, Tianjin Third Central Hospital, Tianjin, China;Renal Division, Peking University First Hospital, Beijing, China;Renal Department, Hebei Medical University Forth Hospital, Hebei, China;Renal Department, Beijing Puren Hospital, Beijing, China;Renal Department, Tianjin Medical University General Hospital, Tianjin, China;Renal Department, Beijing Aerospace General Hospital, Beijing, China

关键词: Randomized controlled trial;    Body composition monitor;    Dry weight;    Bioimpedance;    Hemodialysis;   

Others  :  1083091
DOI  :  10.1186/1471-2369-13-120

 received in 2012-09-11, accepted in 2012-09-14,  发布年份 2012

【 摘 要 】

Background

Bioimpedance analysis (BIA) has been reported as helpful in identifying hypervolemia. Observation data showed that hypervolemic maintenance hemodialysis (MHD) patients identified using BIA methods have higher mortality risk. However, it is not known if BIA-guided fluid management can improve MHD patients’ survival. The objectives of the BOCOMO study are to evaluate the outcome of BIA guided fluid management compared with standard care.

Methods

This is a multicenter, prospective, randomized, controlled trial. More than 1300 participants from 16 clinical sites will be included in the study. The enrolment period will last 6 months, and minimum length of follow-up will be 36 months. MHD patients aged between 18 years and 80 years who have been on MHD for at least 3 months and meet eligibility criteria will be invited to participate in the study. Participants will be randomized to BIA arm or control arm in a 1:1 ratio. A portable whole body bioimpedance spectroscopy device (BCM—Fresenius Medical Care D GmbH) will be used for BIA measurement at baseline for both arms of the study. In the BIA arm, additional BCM measurements will be performed every 2 months. The primary intent-to-treat analysis will compare outcomes for a composite endpoint of death, acute myocardial infarction, stroke or incident peripheral arterial occlusive disease between groups. Secondary endpoints will include left ventricular wall thickness, blood pressure, medications, and incidence and length of hospitalization.

Discussions

Previous results regarding the benefit of strict fluid control are conflicting due to small sample sizes and unstable dry weight estimating methods. To our knowledge this is the first large-scale, multicentre, prospective, randomized controlled trial to assess whether BIS-guided volume management improves outcomes of MHD patients. The endpoints of the BOCOMO study are of utmost importance to health care providers. In order to obtain that aim, the study was designed with very careful important considerations related to the endpoints, sample size, inclusion criteria, exclusion criteria and so on. For example, annual mortality of Beijing MHD patients was around 10%. To reach statistical significance, the sample size will be very large. By using composite endpoint, the sample size becomes reasonable and feasible. Limiting inclusion to patients with urine volume less than 800 ml/day the day before dialysis session will limit confounding due to residual renal function effects on the measured parameters. Patients who had received BIS measurement within 3 months prior to enrolment are excluded as data from such measurements might lead to protocol violation. Although not all patients enrolled will be incident patients, we will record the vintage of dialysis in the multivariable analysis.

Trial registration

Current Controlled Trials NCT01509937

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009, 24(5):1574-1579. England
• [2]Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002, 62(3):1046-1053. United States
• [3]Puskar D, Pasini J, Savic I, Bedalov G, Sonicki Z: Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J. 2002, 43(3):306-311. Croatia
• [4]Mizumasa T, Hirakata H, Yoshimitsu T, Hirakata E, Kubo M, Kashiwagi M, Tanaka H, Kanai H, Fujimi S, Iida M: Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. Nephron Clin Pract 2004, 97(1):c23-c30. Switzerland
• [5]John AS, Tuerff SD, Kerstein MD: Nonocclusive mesenteric infarction in hemodialysis patients. J Am Coll Surg 2000, 190(1):84-88. UNITED STATES
• [6]Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004, 66(3):1212-1220. United States
• [7]Tisler A, Akocsi K, Harshegyi I, Varga G, Ferenczi S, Grosz M, Kulcsar I, Locsey L, Samik J, Solt I, Szegedi J, Toth E, Wagner G, Kiss I: Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res 2002, 25(2):97-102. Switzerland
• [8]Pillon L, Piccoli A, Lowrie EG, Lazarus JM, Chertow GM: Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int 2004, 66(3):1266-1271. United States
• [9]Movilli E, Gaggia P, Zubani R, Camerini C, Vizzardi V, Parrinello G, Savoldi S, Fischer MS, Londrino F, Cancarini G: Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007, 22(12):3547-3552. England
• [10]Chamney PW, Kramer M, Rode C, Kleinekofort W, Wizemann V: A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int 2002, 61(6):2250-2258. United States
• [11]Ozkahya M, Ok E, Toz H, Asci G, Duman S, Basci A, Kose T, Dorhout MEJ: Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant 2006, 21(12):3506-3513. England
• [12]Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF Jr: Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005, 16(7):2162-2169. United States
• [13]Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009, 53(3):500-507. United States
• [14]Charra B: Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 2007, 11(1):21-31. Canada
• [15]Moissl UM, Wabel P, Chamney PW, Bosaeus I, Levin NW, Bosy-Westphal A, Korth O, Muller MJ, Ellegard L, Malmros V, Kaitwatcharachai C, Kuhlmann MK, Zhu F, Fuller NJ: Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas. 2006, 27(9):921-933. England
• [16]den Ham ECv, Kooman JP, Christiaans MH, Nieman FH, Van Kreel BK, Heidendal GA, Van Hooff JP: Body composition in renal transplant patients: bioimpedance analysis compared to isotope dilution, dual energy X-ray absorptiometry, and anthropometry. J Am Soc Nephrol 1999, 10(5):1067-1079. UNITED STATES
• [17]McClanahan BS, Stockton MB, Lanctot JQ, Relyea G, Klesges RC, Slawson DL, Schilling LP: Measurement of body composition in 8-10-year-old African-American girls: a comparison of dual-energy X-ray absorptiometry and foot-to-foot bioimpedance methods. Int J Pediatr Obes 2009, 4(4):389-396. England
• [18]Lintsi M, Kaarma H, Kull I: Comparison of hand-to-hand bioimpedance and anthropometry equations versus dual-energy X-ray absorptiometry for the assessment of body fat percentage in 17-18-year-old conscripts. Clin Physiol Funct Imaging. 2004, 24(2):85-90.
• [19]Kraemer M: A new model for the determination of fluid status and body composition from bioimpedance measurements. Physiol Meas 2006, 27(9):901-919. England
• [20]Dou YN, Cheng XY, Liu L, Bai XF, Wu LY, Guo WY, Zhao XJ, Wang F, Cao LY, Zuo L: Development and Validation of a New Dry Weight Estimation Method Using Single Frequency Bioimpedance in Hemodialysis Patients. Blood Purification 2011, 32:278-285.
• [21]Guida B, De Nicola L, Trio R, Pecoraro P, Iodice C, Memoli B: Comparison of vector and conventional bioelectrical impedance analysis in the optimal dry weight prescription in hemodialysis. Am J Nephrol 2000, 20(4):311-318. SWITZERLAND